Infigratinib
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Trial Timeline
Oct 19, 2023 → May 31, 2024
NCT ID
NCT06206278About Infigratinib
Infigratinib is a phase 2 stage product being developed by LianBio for Gastric Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT06206278. Target conditions include Gastric Cancer, Gastroesophageal Junction Adenocarcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06206278 | Phase 2 | Terminated |
| NCT05019794 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Gastric Cancer